TrialPanorama/Dataset huggingface dataset:
Please select the eligibility criteria that correspond to the clinical trial below.
Title: N/A
Brief Summary: To evaluate the effectiveness of a Head Start-based early intervention for designed to improve asthma management skill and practices of parents, pre-school children and Head Start staff.


Options:
A: Inclusion Criteria:

* NYHA classification of II or III
* LVEF of 40% or less

Exclusion Criteria:

* Uncertain 12-month prognosis
* Potential cardiac transplant within 1 year of study entry
* Severe aortic stenosis
* Uncontrolled ventricular tachycardia
* Non-cardiac causes of heart failure symptoms (i.e., peripheral vascular disease, chronic obstructive pulmonary disease, and arthritis)
* Major psychiatric co-morbidity
* Unstable angina, myocardial infarction, coronary artery bypass graft, or percutaneous transluminal coronary angioplasty within 1 month prior to study entry
B: Inclusion Criteria:

* Male or female patients \>= 18 years
* Females must be either post-menopausal for one year, surgically sterile or using effective contraceptive methods (e.g. barrier method with spermicide, intra-uterine device, hormonal contraceptives).
* Patients with mild essential hypertension: Systolic blood pressure ≥ 140 mmHg and \< 170 and/or diastolic blood pressure ≥ 90 mmHg and \< 105 mmHg"

Exclusion Criteria:

* Moderate and severe hypertension
* Pregnant or nursing women
* A history of cardiovascular disease, including angina pectoris, myocardial infarction, coronary artery bypass graft, percutaneous transluminal coronary angioplasty, transient ischemic attack, stroke, and heart failure NYHA II - IV

Other protocol-defined inclusion/exclusion criteria may apply
C: Inclusion Criteria:

1. current 9-item Patient Health Questionnaire (PHQ-9) score of 10 or more and
2. current treatment in the HIV clinic.

Exclusion Criteria:

1. patients who do not have access to a telephone,
2. patients with current suicidal ideation,
3. patients with significant cognitive impairment as indicated by a score \< 10 on the HIV Dementia Scale, and
4. patients with a chart diagnosis of schizophrenia.
D: 1. Age 2-12 years.
2. A current diagnosis of asthma or reactive airway disease
3. Resident of Baltimore City.
4. Two or more ED visits at the JHPED for asthma in the past 12 months, or hospitalization for asthma at the JHPED in the past 12 months by parent report.
5. Not currently participating in other research studies (participation in previous studies will be noted).

Answer: D
Please select the eligibility criteria that correspond to the clinical trial below.
Title: N/A
Brief Summary: To evaluate the effectiveness of a Head Start-based early intervention for designed to improve asthma management skill and practices of parents, pre-school children and Head Start staff.


Options:
A: 1. Age 2-12 years.
2. A current diagnosis of asthma or reactive airway disease
3. Resident of Baltimore City.
4. Two or more ED visits at the JHPED for asthma in the past 12 months, or hospitalization for asthma at the JHPED in the past 12 months by parent report.
5. Not currently participating in other research studies (participation in previous studies will be noted).
B: Inclusion Criteria:

* Age 1-18 years
* History of Asthma:
* At least 2 prior episodes of bronchodilator treatment
* No underlying cardiac disease
* No other chronic lung disease
* Residence within Philadelphia city limits
* Discharged from ED after treatment for asthma

Exclusion Criteria:

* Prior study enrollment
* Parent unable to speak English
* No telephone to be reachable for follow-up calls
C: Inclusion Criteria:

* The child was 2-18 years old
* African-American or Latino race/ethnicity for the child (by parental identification)
* Primary residence in a Milwaukee zip code
* ED or inpatient ward admission with a primary diagnosis of asthma.

Exclusion Criteria:

* Significant co-morbidity, including other pulmonary conditions, cardiac pathology, renal abnormalities, diabetes mellitus, epilepsy, and other co-morbidities that might lead to ED visits or hospitalizations, and current enrollment in a case management, intervention, or outreach program for childhood asthma management.
D: Inclusion Criteria:

* Physician diagnosis of asthma
* One or more of the following:

  * Acute visit with the primary diagnosis of asthma within the previous 6 months. (Includes visits to physician's office, emergency department, or any other health care facility.); OR
  * Three or more refills for inhaler medicine in the past 6 months, based on review of pharmaceutical records; OR
  * Diagnosis of asthma based on asthma symptoms and pulmonary function testing.

Exclusion Criteria:

* Other lung disease(s) with a possible reactive component (i.e. chronic obstructive pulmonary disease \[COPD\])
* Any diagnosis requiring chronic systemic steroids
* Enrollment in any other asthma disease management program
* Pregnancy
* Plan to reside at current residence for less than 12 months.

Answer: A
Please select the eligibility criteria that correspond to the clinical trial below.
Title: Surfactant Positive Airway Pressure and Pulse Oximetry Trial (SUPPORT) in Extremely Low Birth Weight Infants
Brief Summary: This study compared the use of continuous positive airway pressure initiated at birth with the early administration of surfactant administered through a tube in the windpipe within 1 hour of birth for premature infants born at 24 to 27 weeks gestation. In addition, these infants within 2 hours of birth, had a special pulse oximeter placed to continuously monitor their oxygen saturation in two different target ranges (85-89% or 91-95%). This study helped determine whether or not these two management strategies affect chronic lung disease and survival of premature infants.


Options:
A: Inclusion Criteria:

* Gestational age 23 0/7 - 27 6/7 weeks
* Postnatal age \< 24 hours

Exclusion Criteria:

* Infant not considered viable (decision made not to administer effective therapies)
* Dysmorphic features or congenital malformations that adversely affect life expectancy or neurodevelopment
* Known or strongly suspected cyanotic heart disease
* Persistent pulmonary hypertension, e.g. associated with pulmonary hypoplasia
* Unlikely to be available for long-term follow-up
B: Inclusion Criteria:

* Gestational age (GA) 24 - 27 6/7 weeks at birth, by best obstetrical
* Receive positive pressure ventilation during delivery room resuscitation

Exclusion Criteria:

* Known major anomalies including that may affect measured cardiorespiratory parameters: congenital diaphragmatic hernia, trachea-oesophageal fistula, cyanotic heart disease, pulmonary hypoplasia
* RFM not available during resuscitation
C: Inclusion Criteria:

* gestational age at birth \<34+1/7weeks
* invasive mechanical ventilation OR noninvasive ventilation OR continous positive airway pressure support
* Fraction of inspired oxygen above 0.21 before inclusion
* more than 2 hypoxaemic events (arterial oxygen saturation below 80%) within 8 hours before inclusion
* parental written informed consent

Exclusion Criteria:

* congenital pulmonary anomalies
* diaphragmatic hernia or other diaphragmatic disorders
D: Inclusion Criteria:

* Infants with a minimal gestational age of 24 weeks 0 days to 27 completed weeks (up to 27 6/7ths) by best obstetrical estimate
* Infants who will receive full resuscitation as necessary, i.e., no parental request or physician decision to forego resuscitation
* Infants whose parents/legal guardians have provided consent for enrollment, or
* Infants without known major congenital malformations

Exclusion Criteria:

* Any infant transported to the center after delivery
* Infants whose parents/legal guardians refuse consent
* Infants born during a time when the research apparatus/study personnel are not available
* Infants \< 24 weeks 0 days or \> 28 weeks 0 days, completed weeks of gestation

Answer: D
Please select the eligibility criteria that correspond to the clinical trial below.
Title: Surfactant Positive Airway Pressure and Pulse Oximetry Trial (SUPPORT) in Extremely Low Birth Weight Infants
Brief Summary: This study compared the use of continuous positive airway pressure initiated at birth with the early administration of surfactant administered through a tube in the windpipe within 1 hour of birth for premature infants born at 24 to 27 weeks gestation. In addition, these infants within 2 hours of birth, had a special pulse oximeter placed to continuously monitor their oxygen saturation in two different target ranges (85-89% or 91-95%). This study helped determine whether or not these two management strategies affect chronic lung disease and survival of premature infants.


Options:
A: Inclusion Criteria:

* Infants with a minimal gestational age of 24 weeks 0 days to 27 completed weeks (up to 27 6/7ths) by best obstetrical estimate
* Infants who will receive full resuscitation as necessary, i.e., no parental request or physician decision to forego resuscitation
* Infants whose parents/legal guardians have provided consent for enrollment, or
* Infants without known major congenital malformations

Exclusion Criteria:

* Any infant transported to the center after delivery
* Infants whose parents/legal guardians refuse consent
* Infants born during a time when the research apparatus/study personnel are not available
* Infants \< 24 weeks 0 days or \> 28 weeks 0 days, completed weeks of gestation
B: Inclusion Criteria:

* gestational age at birth less than 28 completed weeks
* cerebral oximeter in place at 3 hours after birth

Exclusion Criteria:

* decision not to provide full life support
C: Inclusion Criteria:

* Preterm neonate \<34+0 weeks after caesarean section
* Decision to conduct full life support
* Written informed consent

Exclusion Criteria:

* No decision to conduct full life support
* No written informed consent
* Congenital malformation
D: Inclusion Criteria:

* Neonates born more than 12 weeks preterm (gestational age up to 27 weeks and 6 days).
* Decision to conduct full life support.
* Possibility to place cerebral NIRS oximeter within 3 hours after birth.
* Obtained parental signed written informed consent.

Exclusion Criteria:

* A clinical decision not to provide full life support.
* No possibility to place the cerebral NIRS oximeter within 3 hours after birth.
* Lack of parental signed written informed consent.

Answer: A
Please select the eligibility criteria that correspond to the clinical trial below.
Title: Surfactant Positive Airway Pressure and Pulse Oximetry Trial (SUPPORT) in Extremely Low Birth Weight Infants
Brief Summary: This study compared the use of continuous positive airway pressure initiated at birth with the early administration of surfactant administered through a tube in the windpipe within 1 hour of birth for premature infants born at 24 to 27 weeks gestation. In addition, these infants within 2 hours of birth, had a special pulse oximeter placed to continuously monitor their oxygen saturation in two different target ranges (85-89% or 91-95%). This study helped determine whether or not these two management strategies affect chronic lung disease and survival of premature infants.


Options:
A: Inclusion Criteria:

* Inborn
* Gestation age 24 0/7 to 34 6/7
* Need for active resuscitation

Exclusion Criteria:

* Prenatally diagnosed cyanotic congenital heart disease
* Non-viable newborns
* Precipitous delivery and resuscitation team not present in the delivery room to initiate resuscitation
B: Inclusion Criteria:

* Gestational age 23 0/7 - 27 6/7 weeks
* Postnatal age \< 24 hours

Exclusion Criteria:

* Infant not considered viable (decision made not to administer effective therapies)
* Dysmorphic features or congenital malformations that adversely affect life expectancy or neurodevelopment
* Known or strongly suspected cyanotic heart disease
* Persistent pulmonary hypertension, e.g. associated with pulmonary hypoplasia
* Unlikely to be available for long-term follow-up
C: Inclusion Criteria:

* Infants with a minimal gestational age of 24 weeks 0 days to 27 completed weeks (up to 27 6/7ths) by best obstetrical estimate
* Infants who will receive full resuscitation as necessary, i.e., no parental request or physician decision to forego resuscitation
* Infants whose parents/legal guardians have provided consent for enrollment, or
* Infants without known major congenital malformations

Exclusion Criteria:

* Any infant transported to the center after delivery
* Infants whose parents/legal guardians refuse consent
* Infants born during a time when the research apparatus/study personnel are not available
* Infants \< 24 weeks 0 days or \> 28 weeks 0 days, completed weeks of gestation
D: Inclusion Criteria:

* Infants \< 28wks gestation

Exclusion Criteria:

* Infants \> 28wks gestation

Answer: C
Please select the eligibility criteria that correspond to the clinical trial below.
Title: Surfactant Positive Airway Pressure and Pulse Oximetry Trial (SUPPORT) in Extremely Low Birth Weight Infants
Brief Summary: This study compared the use of continuous positive airway pressure initiated at birth with the early administration of surfactant administered through a tube in the windpipe within 1 hour of birth for premature infants born at 24 to 27 weeks gestation. In addition, these infants within 2 hours of birth, had a special pulse oximeter placed to continuously monitor their oxygen saturation in two different target ranges (85-89% or 91-95%). This study helped determine whether or not these two management strategies affect chronic lung disease and survival of premature infants.


Options:
A: Inclusion Criteria:

* Birthweight \> 1200 grams
* Chronologic age \< 72 hours.
* Diagnosis of RDS by clinical and radiographic criteria.
* Treated with nasal CPAP and supplemental oxygen \> 30% and not requiring \> 60% FiO2 for longer than 30 minutes to maintain SaO2 88-95%.
* Parental consent.

Exclusion Criteria:

* Birthweight \< 1200 gms.
* Diagnosis other than RDS (e.g., meconium aspiration syndrome).
* Babies who require or have already had endotracheal intubation.
* Babies with congenital anomalies or conditions thought by the attending physician to contribute to respiratory symptoms and/or to restrict adequate spontaneous breathing (e.g., congenital heart disease, obtundation from maternal drugs, certain airway malformations, diaphragmatic hernia).
B: Inclusion Criteria:

* Inborn baby (=born in the hospital)
* Expected ≥ 34-week gestation
* Expected birth weight ≥ 2000 g
* Need for PPV at birth
* Parental consent

Exclusion Criteria:

* Major malformations (incompatible with sustained life or affecting the airways)
C: Inclusion Criteria:

* Infants with a minimal gestational age of 24 weeks 0 days to 27 completed weeks (up to 27 6/7ths) by best obstetrical estimate
* Infants who will receive full resuscitation as necessary, i.e., no parental request or physician decision to forego resuscitation
* Infants whose parents/legal guardians have provided consent for enrollment, or
* Infants without known major congenital malformations

Exclusion Criteria:

* Any infant transported to the center after delivery
* Infants whose parents/legal guardians refuse consent
* Infants born during a time when the research apparatus/study personnel are not available
* Infants \< 24 weeks 0 days or \> 28 weeks 0 days, completed weeks of gestation
D: Inclusion Criteria:

* Mild-to-moderate RDS;
* Postnatal age 2 to 48 hours;
* Gestational age 27 0/7 to 36 6/7 weeks;
* Treated with nasal CPAP modalities ≥ 5 cm H2O and FiO2 between 0.30 and 0.60 for at least 2 hours to maintain SpO2 90-95%;
* Informed consent

Exclusion Criteria:

* Weight \< 800 g;
* Airway anomalies;
* Pulmonary air leaks;
* Craniofacial or cardiothoracic malformations

Answer: C
Please select the eligibility criteria that correspond to the clinical trial below.
Title: Evaluation of the Effect of Position Change During the Withdrawal Phase of Colonoscopy on Adenoma Detection Rate
Brief Summary: The hypothesis to be tested is that position changes during the withdrawal phase of colonoscopy leads to a higher adenoma (polyp) detection rate because of better distension of the colon. Since adenomas are precancerous lesions the enhanced adenoma detection will increase the success of colorectal cancer screening programmes. This study will provide evidence for the value of position changes and encourage endoscopist to adopt position change as a routine in their practice.

May 2007: protocol amendment to include additional prospective analysis using High Definition TV (HDTV).


Options:
A: Inclusion Criteria:

* The patient is undergoing colonoscopy for screening, for surveillance in follow-up of previous polypectomy or for diagnostic workup;
* The patient must understand and provide written consent for the procedure.

Exclusion Criteria:

* Patients with a history of colonic resection;
* Patients with inflammatory bowel disease;
* Patients with a personal history of polyposis syndrome;
* Patients with suspected chronic stricture potentially precluding complete colonoscopy;
* Patients with diverticulitis or toxic megacolon;
* Patients with a history of radiation therapy to abdomen or pelvis;
* Patients who are currently enrolled in another clinical investigation in which the intervention might compromise the safety of the patient's participation in this study.
B: Inclusion Criteria:

* Subject between the ages of 18 and 70
* The patient is undergoing colonoscopy for screening, for surveillance in follow-up of previous polypectomy or for diagnostic workup;
* Written informed consent must be available before enrollment in the trial
* For women with childbearing potential, adequate contraception

Exclusion Criteria:

* Patients with a history of colonic resection;
* Patients with known (or newly diagnosed) inflammatory bowel disease;
* Patients with a personal history of polyposis syndrome;
* Patients with suspected chronic stricture potentially precluding complete colonoscopy;
* Patients with diverticulitis or toxic megacolon;
* Patients with a history of radiation therapy to abdomen or pelvis;
* Patients with acute lower GI bleeding
* Patients who are currently enrolled in another clinical investigation in which the intervention might compromise the safety of the patient's participation in this study.
C: Inclusion Criteria:

* Patients referred ot colonoscopy, age between 50 - 70 years

Exclusion Criteria:

* Patients with colorectal cancer, previous colonic surgery, active colitis and musculoskeletal problems Patients may also be excluded after the first insertion, if painful, routine care will proceed
D: Inclusion Criteria:

* all persons willing and able to undergo screening colonoscopy over the age of 55 years

Exclusion Criteria:

* any condition not compatible with the definition of screening colonoscopy

Answer: C
Please select the eligibility criteria that correspond to the clinical trial below.
Title: Maternal Problem-Solving in Childhood Cancer
Brief Summary: The purpose of this study is to help mothers of children with cancer to cope more effectively by increasing their problem-solving skills.


Options:
A: Inclusion Criteria:

* Mothers of any age with a child diagnosed with any form of cancer 2-16 weeks prior to contact.

Exclusion Criteria:

* Mothers of children with cancer if they do not read or speak English or Spanish, if their child is in severe medical crisis, or if they live a prohibitive distance to complete the intervention.
B: Inclusion Criteria:

* Bachelor student at a Danish University or University College
* A score of 16 or above on the Perceived Stress Scale (PSS)

Exclusion Criteria:

* Smoking
* Psychiatric diagnosis (depression, anxiety, adjustment disorder, PTSD, personality disorder, psychosis).
* Untreated ADHD, autism, abuse and risk of suicide
C: Inclusion Criteria

1. General internal medicine and family physicians
2. In practice for 5-30 years

Exclusion Criteria:

1. physicians who specialize in areas other than general internal medicine and family medicine
2. physicians who have been in practice less than 5 years or more than 30 years
D: Inclusion Criteria:

* Medical doctors across all specialties and professional grades who have a regular contact with patients and works in the United Kingdom.

Answer: A
Please select the eligibility criteria that correspond to the clinical trial below.
Title: Treatment and Prevention of Pericarditis With Colchicine. A Multicenter Double Blind Randomized Trial. The CORP 2 Trial: COlchicine for Recurrent Pericarditis.
Brief Summary: The purpose of the study is to determine whether colchicine is safe and effective in treatment and prevention of recurrent pericarditis after failure of conventional treatment.


Options:
A: Inclusion Criteria:

* Age \> 18years
* Candidate to cardiac surgery but cardiac transplantation
* Informed consent

Exclusion Criteria:

* Atrial fibrillation
* Candidate to cardiac transplantation
* Severe liver disease or elevation of serum transaminases (\> 1.5 times the upper reference limit)
* Serum creatinine \> 2.5 mg/dL
* Preoperative elevation of CK or known myopathy
* Known chronic intestinal diseases or blood dyscrasias
* Pregnancy, Lactation or Women of childbearing potential not protected by a contraception method
* Hypersensitivity to colchicine
* Treatment with colchicine for any cause
B: Inclusion Criteria:

* Patients with the first attack of recurrent pericarditis
* Age≥ 18 years
* Informed consent

Exclusion Criteria:

* Suspected neoplastic, tuberculous, or purulent etiology
* Known severe liver disease and/or elevated transaminases \>1.5 times the upper limit of normality
* Serum creatinine \>2.5 mg/dl
* Serum creatine kinase (CK) over the upper limit of normality or known myopathy
* Known gastrointestinal or blood disease
* Pregnant or lactating women or women not protected by a contraception method
* Known hypersensibility to colchicine
* Treatment with colchicine at enrolment
C: Inclusion Criteria:

* Patients with the second and subsequent attack of recurrent pericarditis,
* Age≥ 18 years,
* Informed consent.

Exclusion Criteria:

* Suspected neoplastic, tuberculous, or purulent etiology,
* Known severe liver disease and/or elevated transaminases \>1.5 times the upper limit of normality,
* serum creatinine\>2.5 mg/dl,
* Serum CK over the upper limit of normality or Known myopathy,
* Known gastrointestinal or blood disease,
* Pregnant or lactating women or women not protected by a contraception method,
* Known hypersensibility to colchicine,
* Treatment with colchicine at the enrolment.
D: Inclusion Criteria:

* Patient's who fulfilled the International Criteria for Behcet's Disease.

Exclusion Criteria:

* major organ involvement
* Hypersensitivity reaction

Answer: C